Norton Healthcare’s Post

Recent type 1 diabetes research out of Finland... "A study conducted at the University of Eastern Finland found distinct signatures in CD8-positive T cells in blood samples from children with newly diagnosed type 1 diabetes and in autoantibody-positive children who later developed type 1 diabetes." "'Our findings suggest that before disease onset, children who later progress to clinical type 1 diabetes have a distinct CD8-positive T-cell profile detectable in their blood samples. It could be envisioned that this is a potential, but eventually failing attempt of the immune system to harness the harmful autoimmune response. In the future, these T-cell signatures could potentially be used to develop better biomarkers for evaluating the risk of developing type 1 diabetes, and who would benefit from preventative immunotherapy. Additionally, a deeper characterization of these interesting cell types is warranted to better understand the type 1 diabetes disease process,' University Teacher Anna-Mari Schroderus, the lead author of the study notes." Read: "Distinct T-cell signatures observed at different stages of type 1 diabetes development" https://lnkd.in/dvX28Ydu #T1D #type1 #type1diabetes #diabetes #ScientificResearch #healthcare #health #researchers

I am happy to share some remarkable insights gathered from my recent interview with Dr. Luis Castaño, a distinguished CIBERDEM researcher and pediatric endocrinologist. During our conversation, I learned about some very exciting advancements in the field of type 1 diabetes treatment that are on the verge of changing how we deal with this condition. 💡 According to Dr. Castaño, we stand at the threshold of a new era in type 1 diabetes care. 🚀 Much like the groundbreaking introduction of insulin a century ago, we're now witnessing another significant big step forward with the emergence of Teplizumab, an anti-CD3 drug approved by the FDA in 2022. 💊 This medication offers a remarkable benefit for patients in the early stages of the disease, providing a substantial two-year delay in its clinical onset. ⏰ Moreover, it holds exciting potential for those already living with type 1 diabetes, preserving insulin secretion shortly after diagnosis and enhancing the efficacy of pancreatic islet transplants. 🏥 One of the key shifts we discussed is the notion of 'early-stage type 1 diabetes'. Formerly referred to as 'type 1 prediabetes', this phase underscores the importance of detecting and intervening before symptoms manifest fully. This proactive approach enables us to safeguard pancreatic function and potentially alter the trajectory of the disease. 🔄 Dr. Castaño and his team at Hospital Universitario Cruces - OSI Ezkerraldea Enkarterri Cruces have played a key role in advancing our understanding of this concept. 🔬 Their work with genetic and immune markers to identify individuals at risk of developing type 1 diabetes represents a significant leap forward. 📈 It's clear that in this journey towards a new era in type 1 diabetes management, early intervention is paramount. ⚠️ In this interview in DiabetesFEDE, Dr. Castaño thoroughly analyzes this new scenario in the management of type 1 diabetes. 📰 #Type1Diabetes #Diabetes #Teplizumab #antiCD3

📢 Just Published! Dive into the intricate relationship between Diabetes Mellitus and Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD) in our latest article titled "The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease". This comprehensive review explores the intertwining mechanisms driving the progression of both conditions, shedding light 💡 on the intricate pathways of insulin resistance, inflammation, and lipotoxicity. Discover how MASLD significantly impacts diabetes risk and complications, while diabetes exacerbates liver fibrosis and hepatocellular carcinoma development in MASLD patients🚨 But it's not all grim news! Our article delves into therapeutic interventions ranging from lifestyle modifications to emerging treatment modalities, offering hope for patients and clinicians alike. However, managing these comorbidities isn't without its challenges, underscoring the need for personalized approaches and a keen focus on cardiovascular ❤️health. Ready to deepen your understanding of these metabolic disorders? Read the full article to gain invaluable insights that can shape clinical practice and policy decisions 👇 https://lnkd.in/gXwEzPdG #Hepatology #Diabetes #MetabolicHealth #MedicalResearch

Semaglutide's impact goes beyond glycemic control! A recent study from the American Diabetes Association reveals a 24% decrease in major kidney disease events in type 2 diabetes patients using Semaglutide. This breakthrough is a game-changer for obesity physicians, highlighting the drug's dual benefits in weight management and kidney health. Integrating Semaglutide into treatment plans could redefine patient outcomes, offering a more holistic approach to tackle both weight issues and comorbid conditions. Learn more: [Link to study] #Semaglutide #DiabetesResearch #HealthcareInnovation

Some really promising results from the SUMMIT trial at AHA 2024 this year regarding GLP-1 agonists and cardiovascular outcomes, including heart failure with preserved ejection fraction (HFpEF). We all know HFpEF is very difficult to treat. Treatment with tirzepatide (Mounjaro/Zepbound) was associated with a 38% reduction in combined risk of cardiovascular death, or worsening heart failure events and improved health status in patients with HFpEF and obesity. We live in an exciting time when more and more promising benefits of GLP-1 medical therapy for patients who are overweight or with obesity continue to emerge. Having treatment options for weight management as wells as reducing cardiovascular disease risk is a huge step! I look forward to reading more about this trial! https://lnkd.in/eAtFeuZs

I'm thrilled to share my latest publication, "Sestrin2 at the Crossroads of Cardiovascular Disease and Diabetes: A Comprehensive Review," now available https://lnkd.in/g8SH2ZRe This comprehensive review explores the pivotal role of Sestrin2 in mediating the complexities between cardiovascular health and diabetes. Dive into the article to discover our insights and conclusions that could pave the way for novel therapeutic strategies. #CardiovascularResearch #DiabetesResearch #MedicalResearch

You've probably heard of the Cardiovascular-Kidney-Metabolic syndrome... but I bet you've never heard of the 'Cardio-Renal-Metabolic-Foot' connection! Don't miss our latest publication in Cardiovascular Diabetology where we pioneer this paradigm changing concept. Heart and kidney disease are at epidemic levels in people with diabetes-related foot ulcers. It's therefore time we revolutionise the approach to managing this high priority group. Our new model of care will tackle both the "at-risk foot" and the "at-risk person" - because treating the foot means treating the whole person. This achievement was made possible thanks to an innovative collaboration between the Centre of Excellence Multidisciplinary Diabetes Foot Ulcer Service and the Centre of Excellence for Cardiometabolic Health at the South Metropolitan Health Service. Together, we are optimising cardiovascular care in diabetes one step at a time. South Metropolitan Health Service, The University of Western Australia, Harry Perkins Institute of Medical Research, Emma Hamilton, Gerry Fegan, Girish Dwivedi Read it here (open access): https://lnkd.in/gamqu9FK

The New England Journal of Medicine publishes Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. From 3,533 participants with type 2 diabetes and chronic kidney disease, at three years those on semaglutide had a 24% reduction in kidney disease events, or death from kidney-related or cardiovascular causes. In addition, risk of major cardiovascular events was 18% lower, death from cardiovascular causes was 29% lower, and the risk of death from any cause 20% lower, in the GLP-1 group. You may recollect that back in October 2023, Novo Nordisk made a statement that it had stopped a major study of semaglutide on kidney disease – the FLOW trial. Sadly though, Black people made up only 4.5% of participants; in America, Black people are three times more likely to have kidney failure than white people. We still have much more work to do. https://lnkd.in/e9Txsv4P

As the yearly American Diabetes Association congress comes to a close today, it’s great to see the Consensus Guidance for Monitoring Persons with Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes being published in Diabetes Care and Diabetology. This consensus statement will be of enormous clinical value when setting up early detection programs for autoimmune Type 1 Diabetes #t1d around the world. Led by Breakthrough T1D and co-authored by well-known names like Åke Lernmark Helena Elding Larsson chantal mathieu and Riitta Veijola combined with the endorsements from European Association for the Study of Diabetes e.V. (EASD) and INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (ISPAD) this is the next step into making early detection for autoimmune #T1D part of the clinical practice. Amazing to see so many people come together and make this a reality. A huge help to all countries to get started on the early detection journey. https://lnkd.in/gHzUGZD9

Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US https://lnkd.in/dY5ZuA9y